Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-06-01
2000-02-15
Moezie, F. T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 3, 514866, 4241981, 424546, 552502, A61K 3825
Patent
active
060253320
ABSTRACT:
Methods are provided for treating or alleviating the symptoms of subjects with psychological disorders, metabolic disorders, chronic stress-related disorders, sleep disorders, conditions associated with sexual senescence, aging, or premature aging by treating such subjects with IGF or mutant IGF either alone or complexed with IGFBP-3. Methods for increasing the levels of DHEA or DHEAS and treating or alleviating the symptoms of subjects with disorders characterized by low levels of DHEA or DHEAS by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are also provided. Methods for increasing the level of T4 and treating or alleviating the symptoms of subjects with disorders characterized by low levels of T3 or T4 by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are additionally provided.
REFERENCES:
patent: 4835147 (1989-05-01), Roberts
patent: 4988675 (1991-01-01), Froesch et al.
patent: 5068224 (1991-11-01), Fryklund et al.
patent: 5077284 (1991-12-01), Loria et al.
patent: 5093317 (1992-03-01), Lewis et al.
patent: 5106832 (1992-04-01), Froesch et al.
patent: 5128320 (1992-07-01), Hahn et al.
patent: 5162198 (1992-11-01), Eich et al.
patent: 5187151 (1993-02-01), Clark et al.
patent: 5200509 (1993-04-01), Spencer et al.
patent: 5202119 (1993-04-01), Clark et al.
patent: 5273961 (1993-12-01), Clark
patent: 5407684 (1995-04-01), Loria et al.
patent: 5407913 (1995-04-01), Sommer et al.
patent: 5407927 (1995-04-01), Morales et al.
patent: 5420112 (1995-05-01), Lewis et al.
patent: 5434134 (1995-07-01), Gluckman et al.
patent: 5527776 (1996-06-01), Carlino et al.
patent: 5527789 (1996-06-01), Nyce
patent: 5534493 (1996-07-01), Gluckman et al.
patent: 5637567 (1997-06-01), Moses et al.
patent: 5736515 (1998-04-01), Bengtsson et al.
Aberg et al., "Increases in tissue levels of ubiquionone in association with peroxisome proliferation" Chem. Biol. Inter. (1996) 99:205-218.
Almenoff et al., "Bronchodilatory effects of ipratropium bromide in patients with tetraplegia" Paraplegia (1995) 33:274-277.
Almenoff et al., "Pulmonary function survey in spinal cord injury: Influences of smoking and level and completeness of injury" Lung (1995) 173:297-306.
Andrews et al., "Contemporary management of depression" Am. J. Med. (1994) 97:6A-24S-6A-32S.
Baker et al., "Effects of an Igfl gene null mutation on mouse reproduction" Mol. Endocrinol. (1996) 10:903-918.
Bauman et al., "Blunted growth hormone response to intravenous arginine in subjects with a spinal cord injury" Horm. Metab. Res. (1994) 26:152-156.
Bauman et al., "Chronic baclofen therapy improves the blunted growth hormone response to intravenous arginine in subjects with spinal cord injury" J. Clin. Endocrinol. Metab. (1994) 78:1135-1138.
Bauman et al., "Disorders of carbohydrate and lipid metabolism in veterans with paraplegia or quadriplegia: A model of premature aging" Metabolism (1994) 43:749-756.
Baxter et al., "Growth hormone-dependent insulin-like growth factor (IGF) binding protein from human plasma differs from other human IGF binding proteins" Biochem. Biophys. Res. Comm. (1986) 139:1256-1261.
Baxter et al., "Structural determinants for binary and ternary complex formation between insulin-like growth factor-I (IGF-I) and IGF binding protein-3" J. Biol. Chem. (1992) 267:60-65.
Bayne et al., "The roles of tyrosines 24, 31, and 60 in the high affinity binding of insulin-like growth factor-I to the type I insulin-like growth factor receptor" J. Biol. Chem. (1990) 265:15648-15652.
Bennett et al., "A double blind placebo controlled study of growth hormone therapy in fibromyalgia" J. Musculoskeletal Pain (1995) Abstract enclosed from Supplement: Myopain '95, Jul. 30-Aug. 3, 1995, San Antonio, Texas, p. 110.
Blum et al., "Plasma IGFBP-3 levels as clinical indicators" Modern Concepts in Insulin-Like Growth Factors (1991) E. M. Spencer, ed., Elsevier, New York, pp. 381-393.
Cascieri et al., "Mutants of human insulin-like growth fator I with reduced affinity for the type I insulin-like growth factor receptor" Biochemistry (1988) 27:3229-3233.
Cascieri et al., "Structural analogs of human insulin-like growth facotr (IGF) I with altered affinity for Type 2 IGF receptors" J. Biol. Chem. (1989) 264:2199-2202.
Castro-Alamancos et al., "Learning of the conditioned eye-blink response is impaired by an antisense insulin-like growth factor I oligonucleotide" Proc. Natl. Acad. Sci. USA (1994) 91:10203-10207.
Castro-Alamancos et al., "Long-term depression of glutamate-induced .gamma.-aminobutyric acid release in cerebellum by insulin-like growth factor I" Proc. Natl. Acad. Sci. USA (1993) 90:7386-7390.
Chuzel et al., "Transcriptional regulation of the lutropin/human choriogonadotropin receptor and three enzymes of steroidogenesis by growth factors" Eur. J. Biochem. (1996) 239:8-16.
Ciavatta et al., "Mouse model of human .beta..sup.0 thalassemia: Targeted deletion of the mouse .beta..sup.maj - and .beta..sup.min -globin genes in embryonic stem cells" Proc. Natl. Acad. Sci. USA (1995) 92:9259-9263.
Daynes et al., "Altered regulation of IL-6 production with normal aging" J. Immunol. (1993) 150:5219-5230.
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition: DSM-IV.sup.TM, American Psychiatric Association, Washington, D.C. Title page and table of contents.
Ferraccioli et al., "Somatomedin C (insulin-like growth factor 1) levels decrease during acute changes of stress related hormones. Relevance for fibromyalgia" J. Rheumatol. (1994) 21:1332-1334.
Flood et al., "Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it" Proc. Natl. Acad. Sci. USA (1992) 89:1567-1571.
Flood et al., "Pregnenolone sulfate enhances post-training memory processes when injected in very low doses into limbic system structures: The amygdala is by far the most sensitive" Proc. Natl. Acad. Sci. USA (1995) 92:10806-10810.
Geders et al., "The effect of cisapride on segmental colonic transit time in patients with spinal cord injury" Am. J. Gatroenterol. (1995) 90:285-289.
Holsboer et al., "Steroid effects on central neurons and implications for psychiatric and neurological disorders" Ann. N.Y. Acad. Sci. (1994) 746:345-361.
Huang et al., "Suppression of the hypothalamus-pituitary somatotrope axis in men with spinal cord injuries" Metabolism (1995) 44:1116-1120.
Kahn et al., "Loss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandin-induced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury" Proc. Natl. Acad. Sci. USA (1996) 93:245-249.
Kamikubo et al., "Similar nuclear factors mediate stimulation of rat thyroglobulin gene transcription by thyrotropin and insulin-like growth factor-1" Mol. Endocrinol. (1990) 4:2021-2029.
Katagiri et al., "The role of cytochrome b.sub.5 in the biosynthesis of androgens by human P450c17" Arch. Biochem. Biophys. (1995) 317:343-347.
Moldofsky et al., "Musculoskeletal symptoms and non-REM sleep disturbance in patients with `Fibrositis Syndrome` and healthy subjects" Psychosom. Med. (1975) 37:341-351.
Mondadori et al., "Delayed emergence of effects of memory-enhancing drugs: Implications for the dynamics of long-term memory" Proc. Natl. Acad. Sci. USA (1994) 91:2041-2045.
Morales et al., "Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age" J. Clin. Endrocrinol. Metab. (1994) 78:1360-1367.
Nathorst-Boos et al., "Elective ovarian removal and estrogen replacement therapy--effects on sexual life, psychological well-being and androgen status" J. Psychosom. Obstet. Gynaecol. (1993) 14:283-293.
Nathorst-Boos et al., "Is sexual life influenced by transdermal estrogen therapy?" Acta Obstet. Gynecol. Scand. (1993) 72:656-660.
Popp et al., "Hematology of a murine .beta.-thalasesemia: A longitudinal study" The New York Acad. Sci. (1985) 445:432-444.
Radulescu, R.T., "Nuclear localization signal in insulin-like growth factor-binding protein type 3" Trends Biochem. Sci. (1994) 19(7):278.
Resnicoff et al., "Rat glioblastoma cells expressing an
Celtrix Pharmaceuticals Inc.
Moezie F. T.
LandOfFree
Method for treating low circulating levels of sex hormone steroi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating low circulating levels of sex hormone steroi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating low circulating levels of sex hormone steroi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1905956